Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 18

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Colony stimulating factors (CSFs): Complex roles in atherosclerosis

Singhal, Aarushi, Subramanian, Manikandan·2019·Cytokine
DOI 10.1016/j.cyto.2017.10.012
Open this paper in CoChat — free account

Abstract

Colony stimulating factors (CSFs) play a central role in the development and functional maturation of immune cells besides having pleiotropic effects on cells of the vascular wall. The production of CSFs is induced by multiple atherogenic and inflammatory stimuli and their expression levels are often correlated positively with advanced atherosclerotic plaques and adverse cardiovascular events in humans suggesting that CSFs play a critical role in the pathophysiology of atherosclerosis progression. Interestingly, recombinant CSFs as well as anti-CSFs are being increasingly used for diverse clinical indications. However, the effect of these novel therapeutics on atherosclerotic plaque progression is not well understood. Herein, we summarize the currently available literature on the complex role of CSFs in various stages of atherosclerosis and emphasize the necessity for conducting further mechanistic studies in animal models of atherosclerosis as well as the need for evaluating the cardiovascular safety of CSF-based therapies in humans.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cyto.2017.10.012

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 92

  1. Lieschke, 1994, Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization, Blood, 84, 1737, 10.1182/blood.V84.6.1737.1737 · DOI
  2. Watari, 1994, Production of human granulocyte colony stimulating factor by various kinds of stromal cells in vitro detected by enzyme immunoassay and in situ hybridization, Stem Cells, 12, 416, 10.1002/stem.5530120409 · DOI
  3. Panopoulos, 2008, Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and ‘emergency' hematopoiesis, Cytokine, 42, 277, 10.1016/j.cyto.2008.03.002 · DOI
  4. Soehnlein, 2008, Neutrophil secretion products pave the way for inflammatory monocytes, Blood, 112, 1461, 10.1182/blood-2008-02-139634 · DOI
  5. van der Does, 2010, LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature, J. Immunol., 185, 1442, 10.4049/jimmunol.1000376 · DOI
  6. Doring, 2015, Neutrophils in atherosclerosis: from mice to man, Arterioscler. Thromb. Vasc. Biol., 35, 288, 10.1161/ATVBAHA.114.303564 · DOI
  7. Dorweiler, 2008, Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima, Thromb. Haemost., 99, 373, 10.1160/TH07-06-0387 · DOI
  8. Ionita, 2010, High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions, Arterioscler. Thromb. Vasc. Biol., 30, 1842, 10.1161/ATVBAHA.110.209296 · DOI
  9. Katsaros, 2015, G-CSF predicts cardiovascular events in patients with stable coronary artery disease, PLoS One, 10, e0142532, 10.1371/journal.pone.0142532 · DOI
  10. Madjid, 2013, Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update, Tex. Heart Inst. J., 40, 17
  11. Leizer, 1990, Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor, Blood, 76, 1989, 10.1182/blood.V76.10.1989.1989 · DOI
  12. Spiel, 2011, Increased platelet aggregation and in vivo platelet activation after granulocyte colony-stimulating factor administration A randomised controlled trial, Thromb. Haemost., 105, 655, 10.1160/TH10-08-0530 · DOI
  13. Huo, 2003, Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E, Nat. Med., 9, 61, 10.1038/nm810 · DOI
  14. Sheridan, 1989, Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation, Lancet, 2, 891, 10.1016/S0140-6736(89)91552-3 · DOI
  15. Valgimigli, 2005, Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile, Eur. Heart J., 26, 1838, 10.1093/eurheartj/ehi289 · DOI
  16. Ince, 2005, Preservation from left ventricular remodeling by front-integrated revascularization and stem cell liberation in evolving acute myocardial infarction by use of granulocyte-colony-stimulating factor (FIRSTLINE-AMI), Circulation, 112, 3097, 10.1161/CIRCULATIONAHA.105.541433 · DOI
  17. Hill, 2005, Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease, J. Am. Coll. Cardiol., 46, 1643, 10.1016/j.jacc.2005.01.067 · DOI
  18. Boyle, 2006, Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up, Int. J. Cardiol., 109, 21, 10.1016/j.ijcard.2005.05.024 · DOI
  19. Haghighat, 2007, Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice, Circulation, 115, 2049, 10.1161/CIRCULATIONAHA.106.665570 · DOI
  20. de Boer, 1999, Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization?, Cardiovasc. Res., 41, 443, 10.1016/S0008-6363(98)00255-7 · DOI
  21. Moreno, 2004, Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability, Circulation, 110, 2032, 10.1161/01.CIR.0000143233.87854.23 · DOI
  22. Sinha, 2014, Effects of G-CSF on serum cholesterol and development of atherosclerotic plaque in apolipoprotein E-deficient mice, Int. J. Clin. Exp. Med., 7, 1979
  23. Uchiyama, 2012, Role of regulatory T cells in atheroprotective effects of granulocyte colony-stimulating factor, J. Mol. Cell. Cardiol., 52, 1038, 10.1016/j.yjmcc.2011.12.016 · DOI
  24. Hasegawa, 2006, G-CSF prevents the progression of atherosclerosis and neointimal formation in rabbits, Biochem. Biophys. Res. Commun., 344, 370, 10.1016/j.bbrc.2006.03.081 · DOI
  25. Matsumoto, 2010, Appropriate doses of granulocyte-colony stimulating factor reduced atherosclerotic plaque formation and increased plaque stability in cholesterol-fed rabbits, J. Atheroscler. Thromb., 17, 84, 10.5551/jat.2279 · DOI
  26. Hu, 2013, Granulocyte colony-stimulating factor promotes atherosclerosis in high-fat diet rabbits, Int. J. Mol. Sci., 14, 4805, 10.3390/ijms14034805 · DOI
  27. Dimmeler, 1998, Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?, Eur. Cytokine Netw., 9, 697
  28. Takai, 2008, Granulocyte colony-stimulating factor has no adverse effects on atherosclerotic lesions in high cholesterol-fed miniature Swine, J. Vet. Med. Sci., 70, 943, 10.1292/jvms.70.943 · DOI
  29. Plenz, 1997, Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery, Arterioscler. Thromb. Vasc. Biol., 17, 2489, 10.1161/01.ATV.17.11.2489 · DOI
  30. Subramanian, 2015, Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling, Circ. Res., 116, e13, 10.1161/CIRCRESAHA.116.304794 · DOI
  31. Sheng, 2014, STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation, Cell Res., 24, 1387, 10.1038/cr.2014.154 · DOI · Paper page
  32. Li, 2015, Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy, Sci. Transl. Med., 7, 10.1126/scitranslmed.aab4176 · DOI
  33. Stanley, 1994, Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology, Proc. Natl. Acad. Sci. USA, 91, 5592, 10.1073/pnas.91.12.5592 · DOI
  34. Shibata, 2001, GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1, Immunity, 15, 557, 10.1016/S1074-7613(01)00218-7 · DOI
  35. King, 2010, GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization, J. Exp. Med., 207, 953, 10.1084/jem.20091844 · DOI
  36. Hercus, 2009, The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease, Blood, 114, 1289, 10.1182/blood-2008-12-164004 · DOI
  37. Guthridge, 2004, The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2, Blood, 103, 820, 10.1182/blood-2003-06-1999 · DOI
  38. Sugiyama, 2001, Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes, Am. J. Pathol., 158, 879, 10.1016/S0002-9440(10)64036-9 · DOI
  39. Biwa, 1998, Induction of murine macrophage growth by oxidized low density lipoprotein is mediated by granulocyte macrophage colony-stimulating factor, J. Biol. Chem., 273, 28305, 10.1074/jbc.273.43.28305 · DOI
  40. Buschmann, 2003, Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor, Circulation, 108, 610, 10.1161/01.CIR.0000074209.17561.99 · DOI
  41. Grundmann, 2006, Granulocyte-macrophage colony-stimulating factor stimulates arteriogenesis in a pig model of peripheral artery disease using clinically applicable infusion pumps, J. Vasc. Surg., 43, 1263, 10.1016/j.jvs.2006.02.049 · DOI
  42. Seiler, 2001, Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study, Circulation, 104, 2012, 10.1161/hc4201.097835 · DOI
  43. Zbinden, 2005, Safety and efficacy of subcutaneous-only granulocyte-macrophage colony-stimulating factor for collateral growth promotion in patients with coronary artery disease, J. Am. Coll. Cardiol., 46, 1636, 10.1016/j.jacc.2005.01.068 · DOI
  44. Becher, 2016, GM-CSF: from growth factor to central mediator of tissue inflammation, Immunity, 45, 963, 10.1016/j.immuni.2016.10.026 · DOI
  45. Wicks, 2016, Targeting GM-CSF in inflammatory diseases, Nat. Rev. Rheumatol., 12, 37, 10.1038/nrrheum.2015.161 · DOI
  46. Zhang, 2013, ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages, Cell Res., 23, 898, 10.1038/cr.2013.75 · DOI
  47. Plenz, 1999, Granulocyte-macrophage colony-stimulating factor (GM-CSF) modulates the expression of type VIII collagen mRNA in vascular smooth muscle cells and both are codistributed during atherogenesis, Arterioscler. Thromb. Vasc. Biol., 19, 1658, 10.1161/01.ATV.19.7.1658 · DOI
  48. Zuckerman, 1992, Cytokine regulation of macrophage apo E secretion: opposing effects of GM-CSF and TGF-beta, Atherosclerosis, 96, 203, 10.1016/0021-9150(92)90066-P · DOI
  49. Zhu, 2009, GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions, J. Exp. Med., 206, 2141, 10.1084/jem.20090866 · DOI
  50. Shindo, 1999, Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits, Circulation, 99, 2150, 10.1161/01.CIR.99.16.2150 · DOI
  51. Brissette, 1995, GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF, Cytokine, 7, 291, 10.1006/cyto.1995.0035 · DOI
  52. Janson, 1991, Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor, J. Immunol., 147, 4218, 10.4049/jimmunol.147.12.4218 · DOI
  53. Finbloom, 1993, Culture of human monocytes with granulocyte-macrophage colony-stimulating factor results in enhancement of IFN-gamma receptors but suppression of IFN-gamma-induced expression of the gene IP-10, J. Immunol., 150, 2383, 10.4049/jimmunol.150.6.2383 · DOI
  54. Eubank, 2004, GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice, Immunity, 21, 831, 10.1016/j.immuni.2004.10.011 · DOI
  55. Nimer, 1988, Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor, JAMA, 260, 3297, 10.1001/jama.1988.03410220081032 · DOI
  56. Ishibashi, 1994, Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor, Arterioscler. Thromb., 14, 1534, 10.1161/01.ATV.14.10.1534 · DOI
  57. Takahashi, 1991, GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase, and cholesterol, Am. J. Hematol., 36, 213, 10.1002/ajh.2830360312 · DOI
  58. Kolodgie, 2003, Intraplaque hemorrhage and progression of coronary atheroma, N. Engl. J. Med., 349, 2316, 10.1056/NEJMoa035655 · DOI
  59. Shaposhnik, 2007, Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions, Arterioscler. Thromb. Vasc. Biol., 27, 621, 10.1161/01.ATV.0000254673.55431.e6 · DOI
  60. Finn, 2010, Concept of vulnerable/unstable plaque, Arterioscler. Thromb. Vasc. Biol., 30, 1282, 10.1161/ATVBAHA.108.179739 · DOI
  61. Ditiatkovski, 2006, GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice, Arterioscler. Thromb. Vasc. Biol., 26, 2337, 10.1161/01.ATV.0000238357.60338.90 · DOI
  62. Baitsch, 2011, Apolipoprotein E induces antiinflammatory phenotype in macrophages, Arterioscler. Thromb. Vasc. Biol., 31, 1160, 10.1161/ATVBAHA.111.222745 · DOI
  63. Kelly, 1994, Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity, Cell. Immunol., 159, 124, 10.1006/cimm.1994.1302 · DOI
  64. Fixe, 1998, M-CSF: haematopoietic growth factor or inflammatory cytokine?, Cytokine, 10, 32, 10.1006/cyto.1997.0249 · DOI
  65. Wiktor-Jedrzejczak, 1990, Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse, Proc. Natl. Acad. Sci. USA, 87, 4828, 10.1073/pnas.87.12.4828 · DOI · Paper page
  66. Clinton, 1992, Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis, Am. J. Pathol., 140, 301
  67. Rosenfeld, 1992, Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans, Am. J. Pathol., 140, 291
  68. Rajavashisth, 1990, Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins, Nature, 344, 254, 10.1038/344254a0 · DOI
  69. Rajavashisth, 1995, Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B, Arterioscler. Thromb. Vasc. Biol., 15, 1591, 10.1161/01.ATV.15.10.1591 · DOI
  70. Saitoh, 2000, Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris, J. Am. Coll. Cardiol., 35, 655, 10.1016/S0735-1097(99)00583-5 · DOI
  71. Stanley, 1983, CSF-1–a mononuclear phagocyte lineage-specific hemopoietic growth factor, J. Cell. Biochem., 21, 151, 10.1002/jcb.240210206 · DOI
  72. Wang, 1988, Induction of monocyte migration by recombinant macrophage colony-stimulating factor, J. Immunol., 141, 575, 10.4049/jimmunol.141.2.575 · DOI
  73. Tushinski, 1982, Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy, Cell, 28, 71, 10.1016/0092-8674(82)90376-2 · DOI
  74. de Villiers, 1994, Macrophage-colony-stimulating factor selectively enhances macrophage scavenger receptor expression and function, J. Exp. Med., 180, 705, 10.1084/jem.180.2.705 · DOI
  75. Motoyoshi, 1989, Serum cholesterol-lowering activity of human monocytic colony-stimulating factor, Lancet, 2, 326, 10.1016/S0140-6736(89)90505-9 · DOI
  76. Schaub, 1994, Recombinant human macrophage colony-stimulating factor reduces plasma cholesterol and carrageenan granuloma foam cell formation in Watanabe heritable hyperlipidemic rabbits, Arterioscler. Thromb., 14, 70, 10.1161/01.ATV.14.1.70 · DOI
  77. Stoudemire, 1991, Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels, Blood, 77, 750, 10.1182/blood.V77.4.750.750 · DOI
  78. Hussaini, 1990, Colony-stimulating factor-1 modulates alpha 2-macroglobulin receptor expression in murine bone marrow macrophages, J. Biol. Chem., 265, 19441, 10.1016/S0021-9258(17)45392-0 · DOI
  79. Smith, 1995, Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E, Proc. Natl. Acad. Sci. USA, 92, 8264, 10.1073/pnas.92.18.8264 · DOI
  80. Qiao, 1997, Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice, Am. J. Pathol., 150, 1687
  81. Rajavashisth, 1998, Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice, J. Clin. Invest., 101, 2702, 10.1172/JCI119891 · DOI
  82. Shaposhnik, 2010, Arterial colony stimulating factor-1 influences atherosclerotic lesions by regulating monocyte migration and apoptosis, J. Lipid Res., 51, 1962, 10.1194/jlr.M005215 · DOI
  83. Murayama, 1999, Intraperitoneal administration of anti-c-fms monoclonal antibody prevents initial events of atherogenesis but does not reduce the size of advanced lesions in apolipoprotein E-deficient mice, Circulation, 99, 1740, 10.1161/01.CIR.99.13.1740 · DOI
  84. Ymer, 1985, Constitutive synthesis of interleukin-3 by leukaemia cell line WEHI-3B is due to retroviral insertion near the gene, Nature, 317, 255, 10.1038/317255a0 · DOI
  85. Plaut, 1989, Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores, Nature, 339, 64, 10.1038/339064a0 · DOI
  86. Lantz, 1998, Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites, Nature, 392, 90, 10.1038/32190 · DOI · Paper page
  87. Rudolph, 2009, Interleukin-3 is elevated in patients with coronary artery disease and predicts restenosis after percutaneous coronary intervention, Int. J. Cardiol., 132, 392, 10.1016/j.ijcard.2007.12.060 · DOI
  88. Brizzi, 2001, Interleukin-3 stimulates migration and proliferation of vascular smooth muscle cells: a potential role in atherogenesis, Circulation, 103, 549, 10.1161/01.CIR.103.4.549 · DOI
  89. Wang, 2014, Interleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiency, Arterioscler. Thromb. Vasc. Biol., 34, 976, 10.1161/ATVBAHA.113.303097 · DOI
  90. Lacey, 2012, Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models, J. Immunol., 188, 5752, 10.4049/jimmunol.1103426 · DOI
  91. Brocheriou, 2011, Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis, Atherosclerosis, 214, 316, 10.1016/j.atherosclerosis.2010.11.023 · DOI
  92. Irvine, 2009, Colony-stimulating factor-1 (CSF-1) delivers a proatherogenic signal to human macrophages, J. Leukoc. Biol., 85, 278, 10.1189/jlb.0808497 · DOI

Cited by

Metadata

Authors
Singhal, A., & Subramanian, M.
Venue
Cytokine
Publisher
Elsevier BV
Published
2019-10
Volume
122
Pages
154190
ISSN
1043-4666
DOI
10.1016/j.cyto.2017.10.012
Cited by
18
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Ramalingaswami Fellowship, Department of Biotechnology, India
  • Council of Scientific and Industrial Research, India (OLP1130)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review